Recent searches
Search options
Administered by:
RT @CornelyOliver@twitter.com
Congratulations to the new kid on the block: Rezafungin non-inferior to caspofungin for cure and mortality. High efficacy from the beginning of treatment. No concerning trends in adverse events. Phase 2 and Phase 3 in line. https://twitter.com/MSG_ERC/status/1596292422082101248
: https://twitter.com/CornelyOliver/status/1596406604609589248
TwitterMSGERC on Twitter“ReSTORE trial was a phase 3 RCT of caspofungin vs rezafungin (a once-weekly echinocandin) for invasive #candidiasis including #candidemia
#Rezafungin was non-inferior for primary endpoints of d14 global cure and 30d all-cause mortality
https://t.co/Lh1fQsc2Vm”
@TransplantIDNet@med-mastodon.comThis @TheLancetInfDis@twitter.com study of once-weekly rezafungin may be a great new option for #candida when oral azoles resistant or contraindicated. Avoid a PICC when a central line might have even been the source!
In the "Antifungals" and "Candida" folders http://transplantid.net
www.zotero.orgZotero | Your personal research assistant